Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/08/056169
CTRI/2023/08/056169
Not yet recruiting
Phase 3

Adjuvant HD-tDCS for social cognition in schizophrenia and its correlation with serum oxytocin: A randomised sham controlled study - NI

Central Institute of Psychiatry0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: F202- Catatonic schizophreniaHealth Condition 2: F201- Disorganized schizophreniaHealth Condition 3: F208- Other schizophreniaHealth Condition 4: F200- Paranoid schizophreniaHealth Condition 5: F205- Residual schizophreniaHealth Condition 6: F209- Schizophrenia, unspecifiedHealth Condition 7: F203- Undifferentiated schizophrenia

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: F202- Catatonic schizophreniaHealth Condition 2: F201- Disorganized schizophreniaHealth Condition 3: F208- Other schizophreniaHealth Condition 4: F200- Paranoid schizophreniaHealth Condition 5: F205- Residual schizophreniaHealth Condition 6: F209- Schizophrenia, unspecifiedHealth Condition 7: F203- Undifferentiated schizophrenia
Sponsor
Central Institute of Psychiatry
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease\-11th edition (ICD\-11, World Health Organization,1993\)
  • •2\.Males aged between 18\- 60 years
  • •3\.Illness duration of equal to or more than 2 years.
  • •4\.Patients giving written informed consent.
  • •5\.Right handed.
  • •6\.The Positive and Negative Syndrome Scale for Schizophrenia (PANSS), positive score less than 11\.
  • •7\.Calgary Depression Scale for Schizophrenia (CDSS) score less than7\.

Exclusion Criteria

  • •1\.Co\-morbid neurological or any other medical or psychiatric disorder
  • •2\.History of substance abuse(except nicotine and caffeine)
  • •3\.History of epilepsy, significant head injury or any other neurosurgical procedures
  • •4\.Patients who have received electroconvulsive therapy or neuromodulation techniques in the past one month
  • •5\.Having any metallic implants in body

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Treatment of Social Cognition in Schizophrenia TrialSchizophrenia
NCT02246426Posit Science Corporation149
Not yet recruiting
Not Applicable
Improving Social Functioning in Schizophrenia through Social Cognitive RemediatioSocial cognitive deficitsSchizophreniaMental Health - Schizophrenia
ACTRN12610000387022Deakin University40
Completed
Not Applicable
RC2S+: Remediation of Social Cognitive ImpairmentsSchizophrenia
NCT02976077Hôpital le Vinatier50
Recruiting
Not Applicable
Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in SchizophreniaSchizophrenia
NCT04267003University of California, Davis160
Active, not recruiting
Phase 1
Enhancing social skills in schizophrenia spectrum disorders – two-arm, double-blind, randomized clinical trial investigating oxytocin vs. placebo as an add-on to an individualized psychosocial treatment (OXY-APS)schizophrenia or other primary psychotic disorders (SSD)Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
CTIS2023-509433-40-00Zentralinstitut Fuer Seelische Gesundheit98